Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197767 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02197767: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT02197767 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02197767, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This pilot study is being done to see if the study medication, Rituximab, preserves kidney function after 12 months of taking the drug.
Interventions
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02197767
The ClinicalTrials.gov registry entry for NCT02197767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT02197767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02197767 about?
NCT02197767 is a clinical study titled "Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis". This pilot study is being done to see if the study medication, Rituximab, preserves kidney function after 12 months of taking the drug.
What is the current status of trial NCT02197767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2014-11. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02197767?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT02197767?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.